ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Rheumatologist in India Finds the Patient Global Assessment Challenging

Anand N. Malaviya, MD, FRCP, ACR Master  |  November 12, 2020

It was a delight to read the comments in the May 2019 issue of The Rheumatologist on a paper by Hirsch and colleagues, discussing how health literacy affects the patient global assessment.1,2 Patient-driven outcome measures (PROs), patient global assessment on a visual analog scale (VAS) or a numeric rating scale (NRS), a segmented numeric version…

Filed under:Conditions Tagged with:health literacypatient global assessment

The 2020 ACR Awards of Distinction & Masters Class

Linda Childers  |  November 12, 2020

Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

Filed under:Awards Tagged with:ACR Convergence 2020Ciarán M. DuffyDr. Abby AbelsonDr. Ami Aalok ShahDr. Andras PerlDr. Angela TincaniDr. Bernardo A. Pons-EstelDr. Brian F. MandellDr. Carlos J. LozadaDr. Daniel SolomonDr. Edward K.L. ChanDr. Emily IsaacsDr. James O’DellDr. James R. SeiboldDr. James WitterDr. Joanne M. JordanDr. Kara PetersenDr. Kathleen M. O’NeilDr. Leonard H. SigalDr. M. Virginia PascualDr. Martin Jan BergmanDr. Michael B. BrennerDr. Nancy E. LaneDr. Norman T. IlowiteDr. Pamela WeissDr. Pierre MiossecDr. Robert W. WarrenDr. Sheldon SolomonDr. Stuart Kassan

ACR Convergence 2020: Study Data for Lupus & Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  November 9, 2020

ACR CONVERGENCE 2020—At the annual meeting’s second Plenary Session, Saturday, Nov. 7, speakers highlighted phase 2 results of a potential new biologic for systemic lupus erythematosus (SLE), as well as data on remission maintenance in rheumatoid arthritis (RA) after withdrawal of etanercept or methotrexate. Phase 2 Trial of Monoclonal Antibody for Lupus (LILAC) Several converging…

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2020ACR Convergence 2020 - SLEACR Convergence 2020 – RA

Gout: The State of the Science

Keri Losavio  |  October 26, 2020

In light of the release of the ACR’s new gout guideline, it’s not surprising that 50 abstracts of studies on various aspects of gout were accepted at ACR Convergence 2020. Here, we highlight just a few:

Filed under:ACR ConvergenceGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2020 – Gout

FDA Approves Golimumab for Patients with pJIA & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2020

The FDA has approved golimumab for the treatment of pediatric patients with active polyarticular juvenile idiopathic arthritis or active psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPediatric Conditions Tagged with:FDA approvalGolimumabPediatricpolyarticular juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis (JIA)psoriatic arthritisU.S. Food and Drug Administration (FDA)

Reflections on Starting a Rheumatology Fellowship During the Pandemic

Nicole K. Zagelbaum Ward, DO, MPH, with Richard S. Panush, MD, MACP, MACR  |  October 19, 2020

Some have opined, cynically, that transformative changes will not come to medical education and training, and to healthcare, until pigs fly. Well, in 2009–10, “swine flu,” and now we are in the midst of an unprecedented and disruptive pandemic, affecting virtually all aspects of our lives, including fellowships.1 As someone who started a rheumatology fellowship…

Filed under:Education & TrainingProfessional Topics Tagged with:Fellows-in-Training

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Case Report: A 40-Year-Old Man with Vasculitic Neuropathy

Martin Garber, DO, & David Fivenson, MD  |  October 19, 2020

Ironically, chronic exposure to minocycline has also been associated with a variety of autoimmune syndromes, including drug-induced lupus, auto­immune hepatitis, serum sickness and vasculitis.1 Minocycline is associated with an 8.5-fold increased risk of drug-induced lupus.2 Minocycline and nitrofurantoin are implicated in 90% of cases of drug-induced autoimmune hepatitis.3 Minocycline-induced vasculitis is much less common and,…

Filed under:ConditionsVasculitis Tagged with:minocyclinepolyarteritis nodosavasculitic neuropathy

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

Arthritis & Rheumatology  |  October 1, 2020

The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.

Filed under:Drug UpdatesResearch Rheum Tagged with:Arthritis & RheumatologyjakinibMethotrexatemonotherapyResearchRheumatoid Arthritis (RA)upadacitinibupadacitinib monotherapy

Rheumatoid Arthritis FocusRheum

Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In June 2021, the ACR released an updated guideline for the treatment of rheumatoid arthritis. The guideline underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Meanwhile, the most recent research in RA is explored by expert…

U.S. & E.U. Differ on Filgotinib for RA

Michele B. Kaufman, PharmD, BCGP  |  September 14, 2020

This summer, the FDA rejected a new drug application for filgotinib to treat RA in the U.S., but a European Medicines Agency committee issued a positive opinion, moving filgotinib closer to authorized use in the E.U.

Filed under:Drug Updates Tagged with:EuropeEuropean UnionFDAfilgotinibRheumatiod arthritisU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 32
  • 33
  • 34
  • 35
  • 36
  • …
  • 107
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences